belimumab   

GtoPdb Ligand ID: 6887

Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B
belimumab is an approved drug (FDA (2011), EMA (2011))
Compound class: Antibody
Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,4] , an immunostimulant essential for normal B cell maintenance and humoral immunity [5], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belimumab

Immunopharmacology Comments
Suppresses B-cell mediated immunity in autoimmune diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Approved drug for SLE.
Sjögren's syndrome Orphanet: ORPHA378
In clinical trial for this indication- see NCT02631538, in combination with rituximab.
Vasculitis Disease Ontology: DOID:865
In clinical trial for this indication- see NCT01663623.
Myositis Disease Ontology: DOID:633
OMIM: 160750
In clinical trial for this indication- see NCT02347891.